Actively Recruiting
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Led by Science Valley Research Institute · Updated on 2025-03-12
100
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Venous thromboembolism (VTE) has a high prevalence in patients with multiple comorbidities undergoing complex surgical procedures. Sometimes, extended prophylaxis for VTE with KLMWH or direct oral anticoagulants (DOACs) is necessary. Currently, there is no consensus in the literature regarding the use of DOACs for extended VTE prophylaxis in patients undergoing lower limb revascularization (LLR). Objective: To evaluate the use of DOACs (already approved to reduce MACE and MALE) in VTE prophylaxis in patients undergoing LLR.
CONDITIONS
Official Title
VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be adults of any age and gender
- Have critical limb ischemia with a planned lower limb revascularization by angioplasty or bypass surgery at HC/EBSERH-UFPE
- Sign the informed consent form
You will not qualify if you...
- Have a symptomatic venous thromboembolism event during hospitalization requiring full anticoagulation
- Have any contraindications to rivaroxaban
- Do not return for the 30-day postoperative follow-up visit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital das Clínicas, Federal University of Pernambuco
Pernambuco, Pernambuco, Brazil, 50740-900
Actively Recruiting
Research Team
G
Gabriela Oliveira Buril, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here